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SUMMARY
This paper reviews the use of hyperfractionated and/or accelerated radiation therapy in the
curative treatment ofnon-small cell lung cancer, and explains the scientific rationale behind the
developmentofthese regimes. Theindications, practicalities and economics ofintroducing them
routinely are addressed. Novel radiotherapy techniques are further discussed in the context of
current developments and on-going clinical trials.
INTRODUCTION
The estimated average incidence of non-small
cell lung cancer in Northern Ireland is over 750
newcasesperyear.1Upto20%ofpatientsmaybe
suitableforasurgicalapproach-ofthosewhodo
have resection (estimated at less than 10% in
Northern Ireland), fewer than half will be long
term survivors. Tumour-related reasons for
inoperabilityincludelocalinvasionandspreadto
mediastinal lymph nodes. Over the last 3 years,
an annual average of 450 patients with lung
cancer were referred to the Northern Ireland
CentreforClinical Oncology (NICCO). In 1994,
331 new lung cancer patients received
radiotherapy treatment. Extrapolating from
fractionation statistics, about 280 patients were
treated forNSCLC, ofwhich 38 received radical
radiotherapy. Thisisinkeepingwitharecognised
figure (~10%) for the proportion of patients
referred for radiotherapy who have stage M/II
disease and are suitable for small volumeradical
radiotherapy. Standard radical radiotherapy
involves treating a planned volume once daily,
five days per week, for up to 6 weeks. In the 30-
40% who have unresectable locally advanced
disease confined to the thorax, survival is ofthe
order of 40% at one year and 15-20% at two
years. Failure rates and patterns have been well
documented,andindicateanintra-thoracicfailure
rate ofup to 48%, depending on stage, histology
andradiationdosedelivered.2Uptothree-quarters
ofthese failed with distant metastases, therefore
the role of systemic chemotherapy continues to
be widely studied. Nonetheless, many die of
uncontrolled intra-thoracic disease and methods
of improving the radiotherapy technique which
might improve survival, need to be pursued. In
recentyearsnon-standardfractionationschedules
have been studied in clinical trials for different
disease sites. In 1997 a large multicentre
prospective randomised controlled trial was
reported in the Lancet describing a highly
significant survival advantage for locally
advanced NSCLC using CHART.3 This regime
involves using smallerfraction sizes, three times
perdayforacontinuous 12dayperiod. There are
obvious practical and economic implications if
this were to be made routinely available. The
potential health gain in this common disease
cannot be ignored.
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BACKGROUND
The concept and advantage of fractionating
radiotherapy was recognised clinically within
the first 25 years after the discovery ofx-rays by
Roentgen in 1895. It was Regaud in France, who
reportedin 1927thataramcouldbesterilisedand
the scrotal skin sparedifx-rays were deliveredin
several smaller daily doses rather than one large
dose.4 This astute observation, although
fundamentallynotapplicabletotreatingatumour
located deep to normal tissue, openedthe doorto
many fractionation experiments in subsequent
years.5
Itwasinthe 1940sthatexperimentalradiobiology
studying mammalian cells in culture, began its
evolution, and very soon the clinical and
laboratoryeffortsbecameclearlycomplementary.
By the 1970s, the concepts of normal tissue
toleranceandtumourcellkineticswerebecoming
much better understood. Attempts were made to
develop mathematicalmodels tohelpexplainthe
phenomena of different tissues responding in
different ways. If this could be done, then
extrapolation might be able to suggest how to
improve further the therapeutic index - in other
words, how togainbettertumourcontrol without
causing further significant damage to the normal
tissues unavoidably encompassed within the
treatment field.6'7 This is precisely the way in
which a better understanding has been achieved,
thus leading to the phase III clinical trials which
are described later.8' 9 Understanding the effects
of radiation at a molecular level may provide
further information on which to develop and
optimise clinical radiotherapy.'0
Although not perfect, it is the linear-quadratic
model on which much has been based to date.
This model is derived from experimental cell
survival curves worked and their shape or
'curviness', as showninFigure 1. Atalowerdose
(D1),moredamageoccursinacutereactingtissues
such as skin ormucosa. Asthedose (perfraction)
increases (D2), there is a higher probability of
damage to late reacting tissues such as spinal
cord, lung orkidney. Reproductive capacity ofa
cell determines its radiobiological survival,
partially determined by its ability to repair sub-
lethal or potentially lethal damage which has
beencausedbyradiation. Invitrohalf-timerepair
ofnormaltissueshasbeenobservedtobebetween
0.5-2.0 hours. When more than one fraction per
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Fig 1. Cell survival curves foracute andlateresponding
responding tissues.
allow maximum normal tissue repair between
fractions, has been calculated to be 3-8 hours.
The theory ofwhat shares atissue's cell survival
curve involves the 'hit' theory of radiation on
DNA, andwhetherasingle-strandedbreak(SSB)
or a double-stranded break (DSB) has occurred.
As the number ofSSBs increases, the likelihood
of that cell not surviving increases linearly,
(represented by a). As the number of DSBs
increases, the likelihood of that cell failing to
replicate increases exponentially, (represented
by f3). From these parameters, a formula can be
derived to closely represent the experimental
observations. An a/f3 ratio can thus also be
derived, and for acute reacting tissues such as
skin and mucosa it is well represented by a high
valueof 10, whereasforlatereactingtissues such
as lung or central nervous system, it is better
represented by a low value ofaround 3. Tumour
cellsresemble acuterespondingtissues, andhave
ahigh cU/f ratio. Ithasbeen observedthatitis the
doseperfraction which is thekey determinantof
late morbidity, whereas the overall treatment
time is important for acute morbidity and effect
on tumour. Itwould seemthatcertaintissues (eg.
spinal cord), have a better capability ofrepair at
lower doses per fraction.
The other aspect of radiobiology which is
important to the understanding of the rationale
behind the design ofcurrent fractionation trials,
is tumour cell kinetics.1' Although it can take
often months for a tumour to clinically double in
size, flow cytometry studies using
bromodeoxyuridine to label cells have shown
that the real or potential doubling time (Tpot) is
of the order of 7 days, (2.3-5 days for lung
tumours). The reason for this discrepancy is that
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90% of the growing tumour cells are shed,
apoptose, differentiate, orsimply donot survive,
and this is known as the 'cell loss factor'. It is
particularly high in squamous cell carcinomas.
Whenadoseofradiationisgiven,manycellswill
be killed, but as a result there will be re-
vascularisation and re- oxygenation of the
remainingcells,allowingimprovednutritionand
thus survivalofaproportionofcellswhichwould
otherwise not have survived. The result of this,
and other factors, is rapid tumour cell
repopulation. Taking these main radiobiological
considerations into account, fractionation
schemes have been developed - low doses per





delivered once each day, five days per week.
Overall treatment times are normally around six
weeks. In hyperfractionation, smaller doses per
fraction are delivered two orthree times perday,
leaving the overall treatment time unchanged.
This approach theoretically allows the total
tumour dose to be escalated without increasing
latemorbidity,therebyimprovingthetherapeutic
index. In a recent review of hyperfractionated
radiotherapy in human tumours, it was
consistentlydemonstratedtobemoreeffectivein
terms of responses than was conventional
radiotherapy. However the methodology used to
collate the information in this review has been
critisized.14 In accelerated radiotherapy,
treatment is delivered in a shorter overall time,
leaving the fraction size unchanged. The theory
behindthisistoreducetheamountoftumourcell
repopulationduringthetreatmentcourse. Several
different strategies may be employed:
1. A straightforward short intensive course -
total dose must be reduced because of
otherwisesignificantlyincreasedacutetissue
toxicity.
2. Split-course technique - a rest period is
introduced between the second and fourth
weekoftreatmentwhichallows acutenormal
tissueregeneration to occur so thattotal dose
does not need to be reduced.
3. Concomitant boost technique - the second
phase or small volume is given concurrently
rather than sequentially.
4. Escalating dose - the total weekly dose is
increased each week. It is thought that the
regeneration ofnormal mucosa is stimulated
early in the treatment course and might
therefore be able to tolerate higher doses as
the course is delivered.
Bycombininghyperfractionationandaccelerated
radiotherapy, continuous hyperfractionated
accelerated radiotherapy or CHART was
developed, represented diagrammatically in
Figure 2,inordertomaximisethepotentialgain.15
This technique uses smaller multiple fractions
per day and therefore a lower overall total dose.
The acute tissue injury occurs only after the
courseiscompleted, andcanthereforebeallowed
to heal and regenerate without the problem of
having to complete treatment.
TheRadiationTherapyOncologyGroup(RTOG)
published a preliminary report of a prospective
randomised study of various irradiation doses
and fractionation schedules in the treatment of
inoperable carcinoma of the lung, in 1980.16
Radiological complete response (CR) rate was
10-25%, and 2-year survival only 12%. From
this, the exploration of novel radiotherapy
scheduleshasmushroomed,inadeterminedeffort
to find the optimum scheduling. Laboratory
studies have played a huge part in painstakingly
and scientifically providing the basis of clinical
studies.
METHODS
The literature was reviewed using Medline, and
authoritative texts reviewed. A search was
conducted for all papers and specifically all
clinicaltrials inhyperfractionated oraccelerated
radiotherapy. Fewer than 15 review articles
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Fig2. Diagramatic representation of standard and
CHART radiotherapy fractionation schedules.
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relating primarily to fractionation of radical
radiotherapy for NSCLC since 1985 were
identified. Inthese, therole ofcombined chemo-
radiation is discussed prominently.
The practical questions of staffing, and changes
required in any radiotherapy department
considering introducing these techniques, is not
adequately addressed, although any additional
costofmultipledailyfractions,hasbeenanalysed
indetailrecently.17Informationwasalsoobtained
from the Radiotherapy Department at NICCO,
from the Northern Ireland Cancer Registry at
Royal Victoria Hospital, and from the Belfast
City Hospital.
CLINICAL TRIALS IN NON-SMALL CELL LUNG
CANCER
Ithas been shownthatimproving local control is
a prerequisite for improving overall survival.'8
AnRTOGpilotstudyin 1985studied 120patients
who were treated with 1.2Gy fractions twice per
day, to total doses ranging form 50.4Gy up to
74.4Gy.19 There was a 13% complete response
rate (CR) and a 33% partial response rate (PR),
although the severe late complication rate was
10% with doses greater than 6OGy. Median
survivaloverallwas7.2months,compatiblewith
other studies giving standard radiation. In 1990,
an RTOG randomised phase I/II trial of 848
patients, comparedtotaldosesrangingfrom6OGy
up to 79.2Gy over 5-61/2 weeks, given again in
1.2Gy fractions twice per day.20 Although sub-
group analysis must be regarded with some
caution, the authors noted that in good
performancestatuspatientswithstageIIIdisease,
asignificantsurvivalbenefitwas seenasthedose
was escalated to 69.6Gy, but not thereafter (2-
year survival of 29% in favourable stage III).




17 patients who were treated with 1.8-2Gy
fractions, twiceperdayto atotal dose of66Gy in
less than fourweeks.21 There was a 40% CR, but
allexperiencedoesophagitis,and24%hadsevere
complications. In another small study, only 12
patients were reported, and four of these had
small cell lung carcinoma.22 The main interest
here was in describing a novel three-times per
day fractionation schedule which achieved the
aim of accelerating treatment but not altering
normal staffing levels. Out ofonly eightpatients
withNSCLCgiven 1.1 Gytwicedaily,therewere
six patients (75%) who achieved a complete
response (CR) at the primary site of disease,
although not all ofthese patients had a CR atthe
nodal site as well.
On the basis of the results of the RTOG
randomised phase I/11 study, a phase III
randomisedtrialwasconducted, andthisincluded
452patientswithinoperableintra-thoracicdisease
(stage 11-111B).23 Standard radiotherapy was
compared to hyperfractionated radiotherapy and
also to induction chemotherapy followed by
standard radiotherapy. In the combined chemo-
radiation arm the median survival was 13.8
months, and was statistically better than the
standard or the hyperfractionated radiotherapy
arms (median survivals of 11.4 and 12.3 months
respectively). However, a recent up-date has
suggested that this benefit was confined to
histologiesotherthansquamouscellcarcinoma.24
Sincetheearlyseventies,theRTOGhasconducted
a number of prospective trials in an attempt to
clarify the role of radiation in NSCLC.2526 In
1988 an RTOG pilot study looked at 56 patients
who were given 75Gy in 28 fractions over five-
and-a-halfweeks.27Dailydosetothemediastinum
was 1.8Gy and2.68Gyto gross tumour. Outof44
patients who received the prescribed dose, there
was a 72.7% response rate with 17 CRs and 15
PRs. Follow-up ranged from 1-3 years; at the
time of reporting, there were nine patients alive
anddisease-freeandfivewhodiedofintercurrent
illness. Twenty-four had died ofknown tumour.
Theconcomitantboosttechnique wastestedinan
RTOG phase I/LI trial in 1993.28 Three hundred
and fifty-five patients were entered, and the total
dose was escalated from 63Gy in 5 weeks (45Gy
plus 18Gy boost) up to 70.2Gy in 5.5 weeks
(50.4Gyplus 19.8Gyboost). Thefinal 114patients
received70.2Gyin5weeks. Severeacutetoxicity
occurred in 2-3% ofpatients, and late morbidity
was up to 9% overall. Two year survival rates
rangedfrom 16% intheearlierpatients to 21% in
the later patients. At a similar stage, a phase I/II
trial involving 37 patients was reported.29 They
were treated with 2Gy fractions twice per day to
a total dose of 5OGy in 4 weeks. There was no
increase in acute or late morbidity and 3-year
survival was 10%. An RTOG phase I/II study of
59 patients with T3/T4 NSCLC, treated with the
concomitant boost technique was reported in
1995.30 Treatment was given on 5 days per week,
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2.68Gy per fraction to the primary tumour over
5.5 weeks. Total dose was 75Gy in 28 fractions.
Mediansurvivalwas 10monthsandonly3patients
had severe late complications. It was concluded
thatthis was afeasibletechnique withacceptable
late toxicity andcomparable survival rates to the
best reported in the literature using either
hyperfractionated radiotherapy or combined
chemo-radiation.
A prospective trial of split course versus
conventionalradiotherapywasreportedin 1995.31
Two hundred and seventy-three consecutive
NSCLC patients were randomised, and all were
staged, treated and followed up by a single
physician in an attempt to maintain uniformity.
No difference in survival was found between the
two arms, median survivals being 11.6 and 10.9
months respectively. The split course arm was
associated with less morbidity.
A pilot study of accelerated hyperfractionated
thoracic radiation therapy (AHTRT) for
unresectable stage III NSCLC was reported in
1993.32Themainendpointwastoxicity. Twenty-
onepatientsweretreatedwith6OGyin40fractions
giving 1.5Gy twice daily with a 2-week break
midway through treatment. The median survival
was 10.8 months. The 1 and2-year survival rates
were 48% and 29% respectively. Three year
survival was 14%. Because ofthese encouraging
results, a further study has since been initiated
comparing standard radiotherapy against
AHTRT +/- chemotherapy.
In 1990, a phase I/IL trial of continuous
hyperfractionated accelerated radiotherapy, or
CHART, wasreported.33 Sixty-two patients with
locally advanced NSCLC received 50.4Gy
escalated up to 54Gy, given in 1.5Gy fractions
three times per day on 12 consecutive days.
Oesophagitis was the only notable complication
butwasnotsevere,and42%wentintoradiological
CR. The 2-year survival was 34%. As aresult of
thesefindings, aphase IIIrandomisedcontrolled
clinical trial was conducted.3 Five hundred and
sixty-three patients were entered, and randomly
allocatedina3:2ratioforCHARTorconventional
radiotherapy(6OGyin30fractionsover6weeks).
Patients with stages IA-IIIB lung cancer and
good performance status were included. Two-
year survival was improved from 20% to 29%o
(p=O.OO04, see figure 1) and subgroup analysis
indicatedthatthelargestbenefitfortheaccelerated
regime occurred in the 82% ofpatients who had
squamous cell carcinoma. In this subgroup, 2-
yearsurvivalincreasedfrom 19%to33%.Overall,
there were no significant differences in acute or
late morbidity. As a follow-on from this,
CHARTWEL (CHART weekend-less) is being
piloted with a view to maintaining the
radiobiological advantage whilst producing less
interference with normal working patterns.
ECONOMIC AND STAFFING IMPLICATIONS
The costoftreating withacourseofradiotherapy
hasnotgenerallybeenasignificantpartofoverall
analyses before, but then recommending routine
out-ofhoursradiotherapytreatmentshasnotuntil
now, beenaprominentissue.34Ithasbeen argued
however, that sub-optimal radiotherapy is more
costly in the long run.35 CHART was used in 10
UK centres during the 2 major trials for both
bronchus and forhead and neck cancer. The cost
ofCHARTversusconventionalradiotherapy was
compared,'7 and CHART was not suprisingly
found to be more expensive. However, for
NSCLC, thedifferencewascalculatedtobe£698
per patient (less if a hostel ward is available,
which is the case at NICCO). If CHARTWEL
proves to be as effective as CHART, then not
only would the cost be reduced further, but the
important issue ofstaffworking times would not
be as significant. It is also acknowledged that
these costsrelate onlytotreatment, andnottothe
longertermgainofdisease-freeoroverallsurvival
which in turn reduces the need forpalliative and
supportive care facilities.
Outof280NSCLCpatientswhohadradiotherapy
in 1994, atNICCO approximately 40hadradical
radiotherapy, and 240 palliative radiotherapy. It
can only be estimated how many out of the 240
would have had locally advanceddisease, and of
those, how many might have been suitable for
CHART. Given that only 5% ofpatients referred
for CHART were suitable for inclusion in the
randomised trial,36 then perhaps 12-15 patients
from this cohort might have been suitable for
entry. Allowing for an increase in the number of
referrals over the last few years, it is projected
that a total of 60-70 patients per year might be
offered an accelerated radiotherapy regime.
Additionaal total funding could therefore be
estimated to be £40,000-£45,000 per year. In
contrast, the expenditure on new chemotherapy
drugs in the UK is estimated to be up to £18,000
per patient treated.37
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OTHER ASPECTS OF RADIATION THERAPY
DEVELOPMENT
The place of more intensive fractionation
schedules has been evaluated in a number of
other situations. The most promising is in head
andneckcancers, althoughthe smallerincidence
and obvious heterogeneity create inherent
difficulties in showing statistical differences in
overall ordisease-free survival. Therehavebeen
encouraging results indicating trends towards
better local control for more advanced disease
(T3/T4).38 39Thereisequivocalevidenceatpresent
inoesophagealcarcinoma,40'41bladdertransitional
cell carcinoma, prostate cancer and malignant
gliomas.
Another main area of development in radiation
oncology, is the use of conformal radiotherapy
(CFRT). Ratherthanusingrectangularfields and
lead shielding to modify the shape of the beam,
multi-leaf collimators (MLCs) have been
developed which enable a more finely shaped
beam to be delivered.42 Three dimensional
treatmentplanning is being used and assessed in
many centres throughout the United States and
Europe.43 Preliminary results for lung cancer
indicate a 2-year cause-specific survival of90%
for stage I/II and 53% for stage IIIA/B.45 With
improvementintechnologyandlowercosts,there
is considerable anticipation.46 In addition,
Intensity Modulated Radiation Therapy (IMRT)
is a yet further advance in the ability to deliver
more precisely shaped dose distributions, and is
created by varying the intensity of the beam
across the treatment field. The first patient was
treated using this technology in Houston, Texas,
in March 1994, andby July 1997, more than 500
patients had been treated using IMRT at 14
institutions.
However,notechnologynorcombinationofother
treatment parameters can make up for
geographically missing microscopic tumour, so
itis therefore vital thatimaging andotheraids to
defining tumour volume and therefore target
volume continue to be actively explored.47 The
logic behind physically reducing the amount of
normal tissue in the treatment volume is self
evident, and dose responses have indeed been
shownforlocallyadvancedNSCLC.48Theability
todoseescalate withoutincreasing normal tissue
damage using a conformal approach is
undoubtedly exciting, however the benefits will
need to be demonstrated by prospective
randomised controlled trials before it should be
recommendedforroutineuseintheUK. Thefirst
of these trials by the Medical Research Council
(MRC) in prostate cancer, is already underway.
The idea of optimising radiotherapy either by
fractionation schedules, beam shaping, or both,
isnowthefocusofmanystudies. Theselectionof
patients most likely to benefit from these
techniques is crucial, and it may be that using
specific assays to determine clonogen doubling
time, patients could be more accurately selected
for CHART (short Tpot) or concomitant boost
acceleratedradiotherapy (longerTpot).49'50Other
waystoenhancethetumourkilleffectofradiation
are with the use of radiosensitisers such as
misonidazole,5' or the concurrent breathing of
carbogenandnicotinamide,52butthesetechniques
remainexperimental.Intraluminalbrachytherapy
(orradiation deliveredfrom a source, ratherthan
external beams) is also ofinterest, but as yet has
no defined place in the radical treatment of
NSCLC.
An interesting concept that is currently under
investigation, is bio-effective dosimetry.53 This
haspotentialtoproducetreatmentplansbasedon
biological effect, rather than absorbed dose, to
any given point. Although there is a long way to
go before this could be introduced to clinical
departments, it is one ofthe many ways in which
theplanning anddelivery ofradiation maybeyet
further advanced.
CHEMOTHERAPY FOR NON-SMALL CELL
LUNG CANCER
The place of systemic chemotherapy in NSCLC
has been widely investigated, and there is now
evidencethatamodestsurvival advantagecanbe
achieved.54 Many investigators are therefore
looking at chemo-radiotherapy combinations,
usingplatinum-basedchemotherapyandintensive
fractionation,55 howevertherearestillreasonable
concerns about toxicity.56 Similarly, with
increasing evidence of benefit for combined
treatment in unresectable oesophageal
carcinoma,57 the possibility of enhancing local
controlevenfurtherwithintensifiedradiotherapy
needs to be investigated. Indeed, the ultimate
search for a combination of optimised
radiotherapy and the most effective systemic
chemotherapy inunresectable tumours, provides
considerable material for on-going and future
clinical trials.
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CONCLUSIONS
While results of surgical resection for early
tumoursaregoodthisdiseasehasapoorprognosis
controllingintra-thoracic tumourinthiscommon
disease should be a priority in cancer research
and management. Of many possible ways, and
combinations ofways, to approach this problem,
CHART has shown a statistically significant
benefit in a large multi-centre randomised
controlledtrial.However,adoptingthistechnique
into routine clinical practice requires more
resources and careful patient selection.58 Two
yearsonafterpublication, onlyafewUKCentres
findthemselves able to offerCHART to selected
patients, and the reasons for this are clearly
outlined in a recent editorial.59 The bottom line
includes difficulties in changing departmental
working hours, and lack of financial support.
There is no real doubt that it ought to be made
available; however the practicalities of its
introduction as an available standard, should not
be underestimated.
Novel and developing radiation therapy must be
incorporated as anintregalpartofmoderncancer
management. It is essential that participation in
national clinical trials is encouraged, that
radiotherapy techniques are optimised, and that
combined modality approaches are able to be
fully supported.
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